openPR Logo
Press release

Idiopathic Pulmonary Fibrosis Market is expected to reach US$ 8.25 Billion by 2033 | Top key players - FibroGen, Inc., Bristol-Myers Squibb Company, AstraZeneca.

09-04-2025 01:04 PM CET | Health & Medicine

Press release from: DataM Intelligence 4Market Research

Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis Market

Market Size and Growth:

The Global Idiopathic Pulmonary Fibrosis Market size reached US$ 4.24 Billion in 2024 from US$ 3.96 Billion in 2023 and is expected to reach US$ 8.25 Billion by 2033, growing at a CAGR of 7.7% during the forecast period 2025-2033.

Idiopathic Pulmonary Fibrosis Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/idiopathic-pulmonary-fibrosis-market?sz

The Idiopathic Pulmonary Fibrosis (IPF) Market refers to the global industry focused on the development, manufacturing, and commercialization of therapies, diagnostics, and supportive treatments for IPF a chronic, progressive lung disease causing scarring of lung tissue. The market encompasses pharmaceuticals, emerging biologics, and patient care solutions aimed at slowing disease progression and improving quality of life.

Industry News of USA and Japan:

USA (June-August 2025)

June 2025: Multiple presentations by Avalyn Pharma Inc. on inhaled therapies for pulmonary diseases at the American Thoracic Society (ATS) conference.

February 2025 (Previous three months): Boehringer Ingelheim's FIBRONEERTM-ILD trial met its primary endpoint, showing a positive effect on forced vital capacity (FVC) in patients.

Japan (June-August 2025)

June 2025: Continued market growth driven by an aging population and increasing prevalence of fibrotic diseases.

August 2025: Market is projected to be valued at USD 3.5 billion, with a significant portion attributed to hospital and clinic settings.

Key Players:

F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim Pharmaceuticals, Inc.
FibroGen, Inc.
Bristol-Myers Squibb Company
AstraZeneca
MediciNova, Inc.

Growth Forecast Projected:

The Global Idiopathic Pulmonary Fibrosis Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Idiopathic Pulmonary Fibrosis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=idiopathic-pulmonary-fibrosis-market

Market Segmentation:

By Treatment: Drugs, Nintedanib, Pirfenidone, Oxygen Therapy, Pulmonary rehabilitation, Lung transplant.

By End-User: Hospitals, ASCs, Clinics and Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/idiopathic-pulmonary-fibrosis-market

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Idiopathic Pulmonary Fibrosis market?

➠ Who are the leading manufacturers in the global Idiopathic Pulmonary Fibrosis industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Idiopathic Pulmonary Fibrosis industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Idiopathic Pulmonary Fibrosis market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis Market is expected to reach US$ 8.25 Billion by 2033 | Top key players - FibroGen, Inc., Bristol-Myers Squibb Company, AstraZeneca. here

News-ID: 4170018 • Views:

More Releases from DataM Intelligence 4Market Research

Point-of-Care Testing Devices Market is expected to reach US$ 101.51 billion by 2033 | Major players - Abbott, F. Hoffmann-La Roche, BD, Danaher Corporation.
Point-of-Care Testing Devices Market is expected to reach US$ 101.51 billion by …
Market Size and Growth: The Global Point-of-Care Testing Devices Market size reached US$ 49.73 billion in 2024 and is expected to reach US$ 101.51 billion by 2033, growing at a CAGR of 8.6% during the forecast period 2025-2033. The Point-of-Care Testing Devices Market encompasses diagnostic tools and technologies that enable rapid, on-site medical testing near the patient, eliminating the need for centralized laboratories. These devices provide immediate results for various conditions, including
Dosing Systems Market is expected to reach US$ 7.55 Billion by 2033 | Major key players - ProMinent, Verder Liquid B.V, Seko, Grundfos
Dosing Systems Market is expected to reach US$ 7.55 Billion by 2033 | Major key …
Market Size and Growth: The Dosing Systems Market size reached US$ 4.72 Billion in 2024 and is expected to reach US$ 7.55 Billion by 2033, growing at a CAGR of 5.3% during the forecast period 2025-2033. The Dosing Systems Market encompasses the global industry involved in the development, manufacturing, and supply of precise fluid or chemical dosing equipment used across various sectors, including water treatment, chemicals, food & beverages, pharmaceuticals, and agriculture.
Electrophysiology Market is expected to reach US$ 22.63 Billion by 2033 | Major Companies - Abbott Laboratories, Medtronic, Boston Scientific Corporation
Electrophysiology Market is expected to reach US$ 22.63 Billion by 2033 | Major …
Market Size and Growth: The Electrophysiology Market reached US$ 9.06 Billion in 2024 and is expected to reach US$ 22.63 Billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033. The Electrophysiology Market encompasses the global industry focused on the diagnosis, monitoring, and treatment of heart rhythm disorders through advanced electrophysiology (EP) procedures, devices, and technologies. It includes EP catheters, mapping systems, ablation equipment, and implantable cardiac devices
Pharmaceutical Sealing Machines Market is expected to reach US$ 2.39 Billion by 2033 | Major Companies - Marchesini Group S.p.A., Uhlmann Pac-Systeme GmbH & Co. KG, MULTIVAC Group
Pharmaceutical Sealing Machines Market is expected to reach US$ 2.39 Billion by …
Market Size and Growth: The Pharmaceutical Sealing Machines Market size reached US$ 1.38 Billion in 2024 and is expected to reach US$ 2.39 Billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033. The Pharmaceutical Sealing Machines Market encompasses the global industry involved in the manufacturing, distribution, and sale of machines designed to seal pharmaceutical products such as tablets, capsules, vials, bottles, and blister packs. These machines ensure

All 5 Releases


More Releases for Pulmonary

Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
03-15-2017 | Health & Medicine
TMR
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments